Vidac Pharma Holding Company Description

Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of anticancer medicines.

The company is developing VDA-1102 CTCL which is in phase 2 clinical trials for the treatment of cutaneous T cell lymphoma (CTCL); and VDA-1102 Ointment, an anti-neoplastic agent that is in phase 2B clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells.

It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that is in preclinical stage for use in the treatment of solid tumors.

Vidac Pharma Holding Plc was founded in 2012 and is headquartered in London, the United Kingdom.

Vidac Pharma Holding Plc

Country	United Kingdom
Founded	2012
Industry	Biological Products, Except Diagnostic Substances
CEO	Max Herzberg

Contact Details

Address: 20-22, Wenlock Road London, N1 7GU United Kingdom
Phone	972 54 4257381
Website	vidacpharma.com

Stock Details

Ticker Symbol	T9G
Exchange	Deutsche Börse Xetra
Reporting Currency	EUR
SIC Code	2836

Key Executives

Name	Position
Max Herzberg	Chief Executive Officer
Shuki Cohen	Chief Financial Officer
Sandra Gamzon	Chief Operating Officer